Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of cyclosporines in the treatment of patients with intraocular lenses

A technology of intraocular lens and cyclosporin, applied in intraocular lens, ophthalmic treatment, cyclic peptide components, etc., can solve problems such as loss of visual acuity and visual quality, image quality degradation, loss of contrast sensitivity, etc.

Inactive Publication Date: 2010-03-31
ALLERGAN INC
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Multifocal IOLs split light energy into near and far focal points, thus resulting in reduced image quality
This can lead to a decrease in image quality with a loss of contrast sensitivity
Furthermore, any irregularities in the surface condition of the ocular surface, such as the surface of the eye, can lead to a loss not only of visual acuity and visual quality, but also of contrast sensitivity
One or more of these drawbacks can lead to significant patient dissatisfaction with the implanted IOL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cyclosporines in the treatment of patients with intraocular lenses
  • Use of cyclosporines in the treatment of patients with intraocular lenses
  • Use of cyclosporines in the treatment of patients with intraocular lenses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0076] Five (5) human patients between the ages of 60-75 were identified with cataracts in one eye. It was decided to surgically remove the natural lens in these eyes and to replace the removed natural lens with a conventional multifocal IOL inserted in the posterior capsule of each eye.

[0077] At least two (2) weeks prior to surgery, topically apply one or more drops to each patient's eye to be operated on, sold by Allergan under the brand name cyclosporin A-containing cream twice daily. The emulsion contained 0.05% by weight cyclosporin A, 1.25% by weight castor oil, 1.0% by weight polysorbate 80 and water.

[0078] The natural lens of each eye was removed using conventional phacoemulsification, which involved making a 3 mm (millimeter) incision in the sclera of the eye. The multifocal IOL was placed in the vacated posterior capsule of each eye using conventional surgical techniques. The IOL is folded or curled and enters the eye through the "incision" described above....

Embodiment II

[0083] This example was designed to evaluate the effect of topical cyclosporine A 0.05% (Restasis; Allergan, Inc.; Irvine, CA) on the quality of vision in patients undergoing cataract surgery with a multifocal lens (IOL).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods of treating a patient are disclosed in which a cyclosporine component is administered to the patient and an intraocular lens is inserted into an eye of the patient. One or more benefits to thepatient may be obtained by practicing the present methods.

Description

[0001] This application is based on and claims priority to US Provisional Patent Application No. 60 / 915,950, filed May 4, 2007, which is incorporated herein by reference. technical field [0002] The present invention relates to methods of treating patients who have received or will receive intraocular lenses. More specifically, the invention relates to methods comprising administering a cyclosporine component to a patient (human or animal) who has received or will receive an intraocular lens. Background technique [0003] The use of cyclosporin A and derivatives of cyclosporin A to treat ophthalmic diseases has been the subject of several patents, such as U.S. Patent 5,474,979 to Ding et al; U.S. Patent 6,254,860 to Garst and U.S. Patent 6,350,442 to Garst, in which The disclosure of each patent is incorporated herein by reference in its entirety. Furthermore, several prior patents have disclosed the use of cyclosporine for the treatment of other conditions and / or diseases...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/13A61F2/16
CPCA61K38/13A61F2/16A61F9/00A61P27/00A61P27/02
Inventor E·D·唐纳费尔德
Owner ALLERGAN INC